Adjuvant Chemotherapy
In general, when using chemotherapy in the adjuvant setting for patients with smaller, node-negative, HER2-negative tumors, what tends to be the most common regimen you use?
In general, when using chemotherapy in the adjuvant setting for patients with smaller, node-negative, HER2-negative tumors, what tends to be the most common regimen you use?
In general, when using chemotherapy in the adjuvant setting for patients with node-positive, HER2-negative tumors, what tends to be the most common chemotherapy regimen you use
In general, when using chemotherapy in the adjuvant setting for patients with node-positive, HER2-negative tumors, what tends to be the most common chemotherapy regimen you use?
What percent of your patients with node-negative breast cancer who receive adjuvant chemotherapy receive regimens that include taxanes?
Where have you received information about TC as reported by the US Oncology Group? (May have more than one response)
Have you utilized the adjuvant TC regimen?
How would you compare TC (docetaxel/ cyclophosphamide) to AC? Antitumor efficacy
How would you compare TC (docetaxel/ cyclophosphamide) to AC? Antitumor efficacy
How would you compare TC (docetaxel/ cyclophosphamide) to AC? Safety and tolerability
How would you compare TC (docetaxel/ cyclophosphamide) to AC? Safety and tolerability
Have you ordered the Onco
type
DX™ assay?
When the Onco
type
DX assay is requested for your patients, who generally initiates the order?
If you had breast cancer and were diagnosed with a 2-cm, ER-positive, node-negative tumor with an Onco
type
DX recurrence score in the intermediate range, how comfortable would you be participating in the TAILORx study, in which you would be randomly assigned to hormonal therapy with or without chemotherapy?
Are you aware of the MammaPrint
®
assay?
